Tesamorelin: The FDA-Approved Growth-Hormone Peptide Behind Egrifta

Tesamorelin is the unusual peptide in the growth-hormone family: it is a real, FDA-approved prescription medicine, sold under the brand name Egrifta, yet it is approved for just one specific condition. It is a stabilized synthetic copy of the body's own growth-hormone-releasing hormone, and it is the only GHRH analog that has cleared FDA review, which is why it gets pulled into so many anti-aging, body-recomposition, and "lose belly fat" conversations - and onto shortlists of the best peptides for muscle growth - that go well beyond what it is actually licensed to do.

This guide is the high-level map of the whole compound. We cover what tesamorelin is, how its mechanism works, the HIV-lipodystrophy indication it is approved for, the visceral-fat trial data behind that approval, the reported and studied doses, side effects, and the honest line between its approved use and its off-label use. Because tesamorelin sits in the same growth-hormone-axis family as several siblings, we keep the shared biology brief and link out: if you want the full GH-axis story, start with our deeper hubs on sermorelin, CJC-1295, and ipamorelin rather than re-reading it here.

Key Takeaways

• Tesamorelin is a stabilized synthetic analog of human growth-hormone-releasing hormone (GHRH), built from all 44 amino acids of GHRH plus a trans-3-hexenoic acid group that slows its breakdown (Wikipedia, "Tesamorelin", retrieved 2026-06-15).
• It is the only FDA-approved GHRH analog, approved in 2010 as Egrifta, made by Theratechnologies, for one indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy (Theratechnologies / PR Newswire, 2010, retrieved 2026-06-15).
• It works by stimulating the body's own growth hormone, binding the GHRH receptor on the pituitary to trigger natural pulsatile GH release, which in turn raises insulin-like growth factor-1 (IGF-1) (FDA / DailyMed Egrifta SV label, retrieved 2026-06-15).
• The pivotal trial showed a real visceral-fat effect: visceral adipose tissue fell about 15.2% with tesamorelin versus a 5.0% rise with placebo over 26 weeks (Falutz et al., New England Journal of Medicine, 2007, retrieved 2026-06-15).
• The approved dose is 2 mg by subcutaneous injection once daily, the dose used in the trials and in the original Egrifta (Falutz et al., NEJM, 2007; FDA / DailyMed, retrieved 2026-06-15).
• Off-label is the catch. Using tesamorelin for general fat loss, anti-aging, or cognition in healthy adults is not FDA-approved; a small trial suggested a cognition signal in older adults, but that use remains investigational (Baker et al., Archives of Neurology, 2012, retrieved 2026-06-15).

What is tesamorelin?

Tesamorelin is a stabilized synthetic version of growth-hormone-releasing hormone (GHRH), the natural signal your brain uses to tell the pituitary gland to release growth hormone. It is the active ingredient in the prescription drug Egrifta. Unlike most peptides in this space, it is FDA-approved, though only for a narrow medical use.

Chemically, tesamorelin contains all 44 amino acids of human GHRH with one important addition: a trans-3-hexenoic acid group attached to the N-terminus (Wikipedia, "Tesamorelin", retrieved 2026-06-15). That extra group is the whole point. Natural GHRH breaks down in the bloodstream within minutes, which makes it impractical as a drug. The hexenoic-acid modification slows that breakdown, so tesamorelin lasts long enough to be injected once a day and still do its job. It is manufactured by the Canadian company Theratechnologies and was first approved by the FDA in 2010 (Theratechnologies / PR Newswire, 2010, retrieved 2026-06-15).

If injectable peptides are new to you, the foundational mechanics live in our how peptides work guide. The single most important framing for tesamorelin is this: it is a genuine approved medicine, but its approval covers one specific patient group, and almost everything else you read about it is off-label.

Citation capsule. Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, comprising all 44 amino acids of GHRH plus a trans-3-hexenoic acid (hexenoyl) group that resists enzymatic degradation. It is a GHRH-receptor agonist that stimulates endogenous growth hormone and raises IGF-1. FDA-approved in 2010 as Egrifta (Theratechnologies) for HIV-associated lipodystrophy. Source: Wikipedia, "Tesamorelin," 2026; FDA/DailyMed Egrifta SV label. CAS 218949-48-5; PubChem CID 16137828.

How does tesamorelin work?

Tesamorelin works by mimicking your body's own GHRH: it binds the GHRH receptor on the pituitary gland, which triggers the natural, pulsatile release of growth hormone, and that growth hormone then raises insulin-like growth factor-1 (IGF-1). It does not replace growth hormone directly; it nudges the gland to make more of its own.

This is the key difference from injecting synthetic growth hormone. Because tesamorelin works one step upstream, it preserves the body's natural rhythm of GH release and its feedback loops, rather than flooding the system with outside hormone. The FDA label describes it plainly: tesamorelin "stimulates the synthesis and release of endogenous growth hormone," with a resulting increase in IGF-1 (FDA / DailyMed Egrifta SV label, retrieved 2026-06-15). The higher GH and IGF-1 then act on fat tissue, which is what drives the reduction in deep abdominal fat seen in the trials.

Here is the chain in plain terms:

• Tesamorelin binds the GHRH receptor on the anterior pituitary, acting like the body's own releasing hormone.
• The pituitary releases its own growth hormone in natural pulses, rather than a constant outside dose.
• Growth hormone raises IGF-1, the downstream hormone that carries out many of GH's effects.
• GH and IGF-1 act on visceral fat, promoting the breakdown of the deep abdominal fat that defines the approved indication.

This is also where tesamorelin differs from its siblings. It is a GHRH analog like sermorelin and CJC-1295, not a ghrelin-mimetic "GH secretagogue" like ipamorelin. We keep the comparison brief here and cover it properly below and in each compound's own hub.

What is tesamorelin used for?

Tesamorelin has exactly one FDA-approved use: reducing excess visceral abdominal fat in adults living with HIV who have lipodystrophy, a fat-redistribution syndrome linked to long-term antiretroviral therapy. Everything else, from general weight loss to anti-aging, is off-label.

Lipodystrophy in HIV is a specific problem: deep visceral fat builds up around the abdominal organs even in people who are otherwise lean, and that visceral fat carries real metabolic risk. Tesamorelin was developed and approved precisely to shrink that deep fat depot, and it remains the only treatment approved in the U.S. for it (Theratechnologies / PR Newswire, 2010, retrieved 2026-06-15). The off-label interest comes from extrapolating that mechanism, since raising your own GH and IGF-1 and targeting deep abdominal fat sounds appealing far beyond the HIV population, but appeal is not the same as approval or proof.

A quick overview of where tesamorelin's various uses stand:

Because each of these off-label directions is a distinct topic, we keep them brief here. The honest headline: tesamorelin has solid evidence for one job and a lot of hopeful extrapolation for the rest.

How strong is the evidence for tesamorelin?

For its approved use, tesamorelin has strong, FDA-grade evidence: large randomized trials showed a clear reduction in visceral fat, which is why it earned approval. For off-label uses in healthy adults, the evidence is far thinner. This split is the most important thing to understand.

The pivotal evidence comes from a Phase 3 trial published in the New England Journal of Medicine. In HIV patients with abdominal fat accumulation, visceral adipose tissue fell by about 15.2% in the tesamorelin group while rising 5.0% in the placebo group over 26 weeks, at the 2 mg daily dose (Falutz et al., New England Journal of Medicine, 2007, retrieved 2026-06-15). That is a genuine, placebo-controlled effect on a hard imaging measure, which is exactly the kind of data the FDA requires and is rare for peptides discussed in this space.

The off-label story is different. For cognition, a single randomized, double-blind, placebo-controlled trial in 152 older adults (some with mild cognitive impairment) found that 20 weeks of tesamorelin improved tests of executive function, with a positive overall effect on cognition (P=.03) (Baker et al., Archives of Neurology, 2012, retrieved 2026-06-15). That is an interesting signal, but it is one study, it did not lead to any approval for cognition, and it does not establish tesamorelin as a cognitive enhancer for healthy people. Notably, that trial used a 1 mg daily dose, half the approved fat-loss dose, which is a reminder that the off-label "protocols" circulating online are not anchored to any validated regimen for those goals.

For broad anti-aging and body-recomposition claims in healthy adults, there is essentially no comparable controlled evidence at all. The reasoning is mostly mechanistic extrapolation: tesamorelin raises GH and IGF-1, GH and IGF-1 are associated with muscle and recovery, therefore tesamorelin should help. That chain is plausible but unproven, and it skips over the fact that the only outcome tesamorelin has demonstrated in a large trial is visceral-fat reduction in a specific patient group, not improved body composition, performance, or longevity in healthy people.

Our take: Tesamorelin is the rare peptide where the approved use rests on real NEJM-grade trial data. The mistake we see is letting that credibility bleed into the off-label uses. "Proven to cut visceral fat in HIV lipodystrophy" does not mean "proven safe and effective for a healthy 40-year-old chasing a leaner midsection."

What doses of tesamorelin are used?

The FDA-approved dose is 2 mg by subcutaneous injection once daily, the same dose used in the pivotal trials and in the original Egrifta. Anything outside the approved HIV indication is off-label and not a recommended dose. The newer Egrifta WR formulation keeps the same active drug while changing how it is reconstituted.

The 2 mg daily dose is well established: it is the dose Falutz and colleagues used and the dose carried into Egrifta (Falutz et al., NEJM, 2007; FDA / DailyMed, retrieved 2026-06-15). The injection is given subcutaneously, with the abdomen as the recommended site, and the cognition study used a smaller 1 mg daily dose for a different goal (Baker et al., Archives of Neurology, 2012, retrieved 2026-06-15). The formulation has evolved over time, which matters because the brand names get confused easily.

The reconstitution, syringe-handling, and injection-technique details are general peptide skills rather than tesamorelin-specific ones, so we keep them at overview level here and point to the how peptides work foundation; to turn a vial strength and target dose into syringe units, use the tesamorelin dosage calculator. The single most important dosing fact is that the only validated, approved dose is the 2 mg HIV-lipodystrophy dose; off-label microdosing protocols you may see online are not approved or trial-validated.

Our take: The formulation history (Egrifta, then Egrifta SV, then Egrifta WR) trips people up, so it is worth saying clearly: it is the same active peptide, tesamorelin. What changed across versions is the mixing and injection logistics, not the molecule.

What are the side effects of tesamorelin?

Because tesamorelin is approved, its side-effect profile is actually documented rather than guessed: the most common issues are injection-site reactions and joint pain, and because it raises IGF-1, it carries cautions around certain conditions. This is real label data, not anecdote.

In the trials, injection-site reactions were the standout, occurring in about 25% of tesamorelin users versus 14% on placebo, and other reported effects included joint pain (arthralgia), pain in the extremities, swelling (peripheral edema), and muscle pain (FDA / DailyMed Egrifta SV label, retrieved 2026-06-15). Because the whole mechanism raises GH and IGF-1, the label carries important cautions: tesamorelin is contraindicated in people with active malignancy, in pregnancy, and where there is disruption of the hypothalamic-pituitary axis, and IGF-1 levels are monitored during use (FDA / DailyMed Egrifta SV label, retrieved 2026-06-15).

A hub-level overview of what is documented:

• Common (label): injection-site redness, itching, or pain; joint pain; limb pain; peripheral edema; muscle pain.
• Metabolic: because it raises IGF-1 and GH, it can affect glucose tolerance, so blood sugar may need monitoring, especially in people at risk.
• Contraindications (label): active cancer, pregnancy, and disruption of the pituitary axis; raising IGF-1 in someone with an active malignancy is a specific concern.
• Off-label uncertainty: in healthy adults using it off-label, the long-term safety of chronically elevating GH and IGF-1 is not established.

This is the hub-level summary; for the ranked community-reported rates next to the real Egrifta label numbers, see the dedicated tesamorelin side effects guide. Anyone considering tesamorelin should review the full prescribing information with a clinician, since the contraindications are not optional fine print.

How does tesamorelin compare to sermorelin, CJC-1295, and ipamorelin?

Tesamorelin sits in the same growth-hormone-axis family as sermorelin, CJC-1295, and ipamorelin, but it stands apart in two ways: it is the only one that is FDA-approved, and it is a full-length, stabilized GHRH(1-44) analog rather than a shorter fragment or a different class of molecule. That regulatory and structural difference is the real story.

In rough terms, sermorelin and CJC-1295 are also GHRH analogs that stimulate the pituitary, but sermorelin is a shorter GHRH(1-29) fragment and CJC-1295 is engineered for a longer duration of action; ipamorelin is a different class entirely, a ghrelin-receptor agonist (a "GH secretagogue") that triggers GH release through a separate pathway. Tesamorelin is the full 44-amino-acid GHRH sequence with the stabilizing hexenoic-acid group, and it is the only member of this group to clear FDA review and carry NEJM-grade trial data for a specific indication (Wikipedia, "Tesamorelin", retrieved 2026-06-15).

That is the hub-level contrast, kept deliberately short to avoid overlapping the dedicated hubs. For a direct head-to-head with the older GHRH fragment, see sermorelin vs tesamorelin, and for the full mechanism, dosing, and use-case detail on each sibling, see sermorelin, CJC-1295, and ipamorelin. The one fact to carry away: tesamorelin is the only one a regulator has actually signed off on, and only for HIV lipodystrophy.

Is tesamorelin safe and legal?

Tesamorelin is a legal, FDA-approved prescription drug for its one indication, which makes it very different from unapproved research peptides; but using it off-label, or buying "research-grade" tesamorelin online, takes you outside that approved, regulated path. The legality hinges entirely on how it is obtained and used.

As a prescription medicine, Egrifta is legitimate, manufactured to pharmaceutical standards, and prescribed for HIV-associated lipodystrophy. A clinician can legally prescribe an approved drug off-label in many cases, but that is a clinical decision made with a doctor, not a green light to self-source. The gray area is the large market selling lyophilized "tesamorelin" vials "for research use only," which sit outside the approved supply chain with no guarantee of identity, purity, or sterility, the same quality risks that apply to any unregulated peptide (Wikipedia, "Tesamorelin", retrieved 2026-06-15). For the broader legal framework and how to evaluate a vendor or a certificate of analysis, see are peptides legal and how to vet peptide quality.

Our take: Tesamorelin's FDA approval gives it a credibility halo the research peptides lack, and that halo is half-earned. The drug is real and approved, but the moment someone uses it off-label for anti-aging or buys an unverified research vial, most of the regulatory protection that approval provides simply does not apply.

How do people obtain tesamorelin?

There are two real-world paths: a legitimate prescription for the approved HIV indication (or a clinician's off-label prescription), and the unregulated research-peptide market that most off-label searches end up in. The first is the safe, regulated route; the second carries the usual quality and legal risks.

For the approved use, tesamorelin is dispensed as Egrifta through normal pharmacy channels with a prescription, though it is expensive as a specialty drug. For off-label goals, some clinics will prescribe it or a compounded version after an evaluation, while a great deal of online supply is "research use only" material of unknown quality. The responsible groundwork is the same as for any peptide:

1. Start with a clinician, who can assess whether tesamorelin is appropriate, review contraindications such as cancer history and pregnancy, and monitor IGF-1 and blood sugar.
2. Confirm the legal status for your country and situation before sourcing anything. See are peptides legal.
3. Demand a certificate of analysis (COA) and learn to read it for identity and purity if you go outside the approved supply. See how to vet peptide quality.
4. Understand the handling basics, since reconstitution and cold storage are not optional. See how peptides work.

We are describing what people do, not endorsing off-label self-sourcing. An approved drug used outside its indication, or an unverified research vial, both carry risks the approval does not cover.

Frequently Asked Questions

The bottom line

Tesamorelin is the most credible peptide in the growth-hormone-axis conversation, and also one of the most misunderstood. It is a genuine FDA-approved medicine, built as a stabilized copy of the body's own GHRH, and it has real NEJM-grade trial data showing it shrinks visceral abdominal fat. In a field crowded with unapproved research chemicals, that approval and that evidence are the exception, not the rule.

The discipline is in the fine print. Tesamorelin is approved for exactly one thing, HIV-associated lipodystrophy, and the popular uses (anti-aging, body recomposition, sharper cognition in healthy adults) are off-label and rest on much thinner evidence, with a side-effect and contraindication profile that should not be ignored. If you take one thing from this hub, let it be the gap between "FDA-approved for HIV lipodystrophy" and "proven safe and effective for whatever I want," and the value of a qualified clinician in navigating it. From here, the natural next reads are the GH-axis siblings sermorelin, CJC-1295, and ipamorelin, plus are peptides legal and how to vet peptide quality.

Sources

• Wikipedia. "Tesamorelin." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Tesamorelin
• Theratechnologies / PR Newswire. "FDA Approves EGRIFTA to Treat Lipodystrophy in HIV Patients." 2010. Retrieved 2026-06-15. https://www.prnewswire.com/news-releases/fda-approves-egrifta-to-treat-lipodystrophy-in-hiv-patients-107084378.html
• U.S. Food and Drug Administration / DailyMed. "EGRIFTA SV (tesamorelin) prescribing information." Retrieved 2026-06-15. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
• Falutz, J., et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine, 2007;357(23):2359-2370. Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
• Baker, L.D., et al. "Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial." Archives of Neurology, 2012;69(11):1420-1429. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/22869065/
• Theratechnologies Inc. "Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8)." 2025. Retrieved 2026-06-15. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin/
• PubChem. "Tesamorelin, CID 16137828." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/16137828